Digital Diagnostics Inc.

Digital Diagnostics Inc.

Digital Diagnostics was founded by Dr. Michael Abramoff, a neuro-ophthalmologist who pioneered the use of computers to diagnose disease. The company is headquartered in Coralville, Iowa, and gained FDA clearance in 2018 for LumineticsCore (formerly IDx-DR) as the first autonomous AI diagnostic system that does not require physician interpretation (per FDA, 2018). The company focuses on AI-driven diagnosis of diabetic retinopathy, a leading cause of blindness. Its core product, LumineticsCore, integrates with electronic health records like EPIC and provides a diagnosis within 30 seconds of image submission. Digital Diagnostics is also researching AI applications for glaucoma, age-related macular degeneration, and cardiovascular disease detection. The firm's technology operates at primary care clinics, where it aims to improve HEDIS quality scores and close care gaps. Digital Diagnostics has deployed its AI across multiple U.S. health systems including Stanford Health System, OSF Healthcare, and Cahaba Medical Care, as well as internationally in Bangladesh. February 2026: The company published a piece on closing the diabetic retinopathy screening gap (per firm newsroom). The company also maintains a research arm publishing real-world evidence on clinical and productivity outcomes. The firm's physician testimonials highlight improved patient adherence and reduced time-to-follow-up from 60 to 5 days. Unlike traditional health-tech firms, Digital Diagnostics operates under a regulatory-first model built around FDA-cleared autonomous AI. This structure separates the company from telemedicine or remote reading services by enabling diagnosis in the exam room without specialist input — a structural differentiator that shifts routine retinal screening from specialty clinics to primary care.